{"id":"NCT03357471","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","officialTitle":"A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-03","primaryCompletion":"2018-07-02","completion":"2018-07-02","firstPosted":"2017-11-30","resultsPosted":"2019-10-25","lastUpdate":"2019-10-25"},"enrollment":70,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Moderate and Severe Active Rheumatoid Arthritis","Active Psoriatic Arthritis","Active Ankylosing Spondylitis","Moderately to Severely Active Crohn's Disease"],"interventions":[{"type":"DRUG","name":"e-Device","otherNames":["Cimzia"]}],"arms":[{"label":"Certolizumab Pegol Q2W injection by e-Device","type":"EXPERIMENTAL"},{"label":"Certolizumab Pegol Q4W injection by e-Device","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.","primaryOutcome":{"measure":"Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2","timeFrame":"Visit 2 (Week 2 for Q2W; Week 4 for Q4W)","effectByArm":[{"arm":"Certolizumab Pegol Q2W Injection by e-Device (SS)","deltaMin":100,"sd":null},{"arm":"Certolizumab Pegol Q4W Injection by e-Device (SS)","deltaMin":96.88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":["33148261"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":[]}}